Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived
- PMID: 1995956
- PMCID: PMC239952
- DOI: 10.1128/JVI.65.3.1634-1637.1991
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived
Abstract
The ability of recombinant vaccinia viruses that separately encoded 9 of the 10 known respiratory syncytial virus (RSV) proteins to induce resistance to RSV challenge was studied in BALB/c mice. Resistance was examined at two intervals following vaccination to examine early (day 9) as well as late (day 28) immunity. BALB/c mice were inoculated simultaneously by the intranasal and intraperitoneal routes with a recombinant vaccinia virus encoding one of the following RSV proteins: F, G, N, P, SH, M, 1B, 1C, or M2 (22K). A parainfluenza virus type 3 HN protein recombinant (Vac-HN) served as a negative control. One half of the mice were challenged with RSV intranasally on day 9, and the remaining animals were challenged on day 28 postvaccination. Mice previously immunized by infection with RSV, Vac-F, or Vac-G were completely or almost completely resistant to RSV challenge on both days. In contrast, immunization with Vac-HN, -P, -SH, -M, -1B, or -1C did not induce detectable resistance to RSV challenge. Mice previously infected with Vac-M2 or Vac-N exhibited significant but not complete resistance on day 9. However, in both cases resistance had largely waned by day 28 and was detectable only in mice immunized with Vac-M2. These results demonstrate that F and G proteins expressed by recombinant vaccinia viruses are the most effective RSV protective antigens. This study also suggests that RSV vaccines need only contain the F and G glycoproteins, because the immunity conferred by the other proteins is less effective and appears to wane rapidly with time.
Similar articles
-
Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.J Virol. 1992 Feb;66(2):1277-81. doi: 10.1128/JVI.66.2.1277-1281.1992. J Virol. 1992. PMID: 1731105 Free PMC article.
-
The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.J Virol. 1993 Feb;67(2):1044-9. doi: 10.1128/JVI.67.2.1044-1049.1993. J Virol. 1993. PMID: 8419638 Free PMC article.
-
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.Vaccine. 1992;10(7):475-84. doi: 10.1016/0264-410x(92)90397-3. Vaccine. 1992. PMID: 1609551
-
Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.J Virol. 1993 Jul;67(7):4086-92. doi: 10.1128/JVI.67.7.4086-4092.1993. J Virol. 1993. PMID: 7685408 Free PMC article.
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
Cited by
-
Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.Antimicrob Agents Chemother. 2016 Oct 21;60(11):6498-6509. doi: 10.1128/AAC.00842-16. Print 2016 Nov. Antimicrob Agents Chemother. 2016. PMID: 27550346 Free PMC article.
-
Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions.J Virol. 2002 Dec;76(23):11931-42. doi: 10.1128/jvi.76.23.11931-11942.2002. J Virol. 2002. PMID: 12414935 Free PMC article.
-
CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.J Virol. 2000 Apr;74(8):3455-63. doi: 10.1128/jvi.74.8.3455-3463.2000. J Virol. 2000. PMID: 10729118 Free PMC article.
-
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.Front Immunol. 2019 Mar 22;10:548. doi: 10.3389/fimmu.2019.00548. eCollection 2019. Front Immunol. 2019. PMID: 30967872 Free PMC article. Review.
-
Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection.Virol J. 2008 Sep 24;5:105. doi: 10.1186/1743-422X-5-105. Virol J. 2008. PMID: 18816384 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources